BR112019019117A2 - métodos e composições para induzir respostas imunes contra clostridium difficile - Google Patents
métodos e composições para induzir respostas imunes contra clostridium difficile Download PDFInfo
- Publication number
- BR112019019117A2 BR112019019117A2 BR112019019117-8A BR112019019117A BR112019019117A2 BR 112019019117 A2 BR112019019117 A2 BR 112019019117A2 BR 112019019117 A BR112019019117 A BR 112019019117A BR 112019019117 A2 BR112019019117 A2 BR 112019019117A2
- Authority
- BR
- Brazil
- Prior art keywords
- toxin
- fact
- protein
- fraction
- multivalent immunogenic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471636P | 2017-03-15 | 2017-03-15 | |
| US62/471,636 | 2017-03-15 | ||
| US201762474434P | 2017-03-21 | 2017-03-21 | |
| US62/474,434 | 2017-03-21 | ||
| PCT/US2018/022597 WO2018170238A2 (en) | 2017-03-15 | 2018-03-15 | Methods and compositions for inducing immune responses against clostridium difficile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019019117A2 true BR112019019117A2 (pt) | 2020-05-05 |
Family
ID=63523217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019019117-8A BR112019019117A2 (pt) | 2017-03-15 | 2018-03-15 | métodos e composições para induzir respostas imunes contra clostridium difficile |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11123419B2 (enExample) |
| EP (1) | EP3595709A4 (enExample) |
| JP (2) | JP7149285B2 (enExample) |
| KR (1) | KR102640722B1 (enExample) |
| CN (1) | CN110691609B (enExample) |
| AU (1) | AU2018236352B2 (enExample) |
| BR (1) | BR112019019117A2 (enExample) |
| CA (1) | CA3056090A1 (enExample) |
| IL (1) | IL269258B2 (enExample) |
| MX (1) | MX2019010948A (enExample) |
| SG (1) | SG11201908376UA (enExample) |
| WO (1) | WO2018170238A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR086199A1 (es) | 2011-04-22 | 2013-11-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| CN110691609B (zh) * | 2017-03-15 | 2024-04-19 | 诺瓦瓦克斯股份有限公司 | 用于诱导针对艰难梭菌的免疫应答的方法和组合物 |
| WO2021255690A2 (en) * | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM873294A0 (en) * | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| WO1999011711A1 (en) * | 1997-09-04 | 1999-03-11 | Eastman Chemical Company | Thermoplastic polyurethane additives for enhancing solid state polymerization rates |
| WO2010017383A1 (en) * | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| WO2011060431A2 (en) | 2009-11-16 | 2011-05-19 | University Of Maryland Baltimore | Multivalent live vector vaccine against clostridium difficile-associated disease |
| US20130039973A1 (en) * | 2011-08-03 | 2013-02-14 | Henry J. Smith | Viral Immunogenic Compositions |
| SG10201602434UA (en) | 2011-09-30 | 2016-05-30 | Novavax Inc | Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| EP2928489B1 (en) | 2012-12-05 | 2019-02-27 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| CN105451762A (zh) | 2013-04-22 | 2016-03-30 | 俄克拉荷马州大学评议会 | 艰难梭菌疫苗及使用方法 |
| EP3524262A1 (en) * | 2013-11-01 | 2019-08-14 | Pfizer Inc | Vectors for expression of prostate-associated antigens |
| BE1022949B1 (fr) * | 2014-06-25 | 2016-10-21 | Glaxosmithkline Biologicals S.A. | Composition immunogene |
| CN106220737B (zh) * | 2016-07-21 | 2020-11-10 | 中国人民解放军军事医学科学院微生物流行病研究所 | 融合蛋白及其在治疗艰难梭菌相关疾病中的应用 |
| CN110691609B (zh) | 2017-03-15 | 2024-04-19 | 诺瓦瓦克斯股份有限公司 | 用于诱导针对艰难梭菌的免疫应答的方法和组合物 |
-
2018
- 2018-03-15 CN CN201880025192.8A patent/CN110691609B/zh active Active
- 2018-03-15 IL IL269258A patent/IL269258B2/en unknown
- 2018-03-15 US US16/494,517 patent/US11123419B2/en active Active
- 2018-03-15 WO PCT/US2018/022597 patent/WO2018170238A2/en not_active Ceased
- 2018-03-15 CA CA3056090A patent/CA3056090A1/en active Pending
- 2018-03-15 BR BR112019019117-8A patent/BR112019019117A2/pt active Search and Examination
- 2018-03-15 SG SG11201908376U patent/SG11201908376UA/en unknown
- 2018-03-15 AU AU2018236352A patent/AU2018236352B2/en active Active
- 2018-03-15 MX MX2019010948A patent/MX2019010948A/es unknown
- 2018-03-15 JP JP2019550687A patent/JP7149285B2/ja active Active
- 2018-03-15 EP EP18767173.0A patent/EP3595709A4/en active Pending
- 2018-03-15 KR KR1020197030108A patent/KR102640722B1/ko active Active
-
2021
- 2021-08-10 US US17/398,610 patent/US11938179B2/en active Active
-
2022
- 2022-09-26 JP JP2022153071A patent/JP7397145B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200085934A1 (en) | 2020-03-19 |
| CN110691609A (zh) | 2020-01-14 |
| WO2018170238A3 (en) | 2018-10-18 |
| EP3595709A4 (en) | 2020-12-23 |
| SG11201908376UA (en) | 2019-10-30 |
| RU2019132111A (ru) | 2021-04-15 |
| CN110691609B (zh) | 2024-04-19 |
| IL269258B1 (en) | 2023-05-01 |
| CA3056090A1 (en) | 2018-09-20 |
| JP2022179543A (ja) | 2022-12-02 |
| IL269258A (en) | 2019-11-28 |
| US11938179B2 (en) | 2024-03-26 |
| WO2018170238A2 (en) | 2018-09-20 |
| EP3595709A2 (en) | 2020-01-22 |
| US11123419B2 (en) | 2021-09-21 |
| MX2019010948A (es) | 2020-01-09 |
| AU2018236352A1 (en) | 2019-10-03 |
| US20220211834A1 (en) | 2022-07-07 |
| RU2019132111A3 (enExample) | 2021-06-29 |
| JP7149285B2 (ja) | 2022-10-06 |
| JP7397145B2 (ja) | 2023-12-12 |
| KR102640722B1 (ko) | 2024-02-26 |
| AU2018236352B2 (en) | 2024-04-04 |
| IL269258B2 (en) | 2023-09-01 |
| JP2020509770A (ja) | 2020-04-02 |
| KR20190125470A (ko) | 2019-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7023248B2 (ja) | 過剰ブレブ形成Ｓｈｉｇｅｌｌａ株 | |
| US11938179B2 (en) | Methods and compositions for inducing immune responses against Clostridium difficile | |
| JP3633933B2 (ja) | 弱毒化細菌における組換え融合タンパク質の発現 | |
| CN104334187B (zh) | 脑膜炎双球菌组合物及其方法 | |
| KR102393038B1 (ko) | OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도 | |
| CN103154242A (zh) | 诺如病毒衍生的免疫原性组合物和方法 | |
| JP2011512152A (ja) | 改善された溶解度を有するＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原 | |
| CN102037135A (zh) | 增强对有鞭毛的细菌的免疫反应的组合物和方法 | |
| KR102041032B1 (ko) | 돼지 생식기 호흡기 증후군 및 돼지 써코바이러스 연관 질환에 대한 백신 조성물 | |
| JP2012532626A (ja) | 無毒化されたＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原 | |
| CA3217591A1 (en) | Coronavirus and influenza compositions and methods for using them | |
| KR20230005265A (ko) | Sars-cov-2에 대한 백신 및 이의 제조 | |
| US9492523B2 (en) | Broadly protective Shigella vaccine based on type III secretion apparatus proteins | |
| CN104560780B (zh) | 产气荚膜梭菌ε毒素减毒突变体及其应用 | |
| US11975061B2 (en) | Protective immunity enhanced Salmonella vaccine (PIESV) against Brucella spp | |
| Agterberg et al. | Outer membrane protein PhoE as a carrier for the exposure of foreign antigenic determinants at the bacterial cell surface | |
| US20190185520A1 (en) | Design of protective anti-zikv vaccine without inducing cross-reactions with dengue | |
| RU2781057C9 (ru) | Способы и композиции для индукции иммунного ответа против clostridium difficile | |
| RU2781057C2 (ru) | Способы и композиции для индукции иммунного ответа против clostridium difficile | |
| TWI605056B (zh) | 用於治療艱難梭狀芽孢桿菌（Clostridium difficile）相關疾病之組成物及方法 | |
| US20150238590A1 (en) | Use of the salmonella spp type iii secretion proteins as a protective vaccination | |
| Li et al. | Construction and immunogenicity evaluation of avian Escherichia coli-derived bacterial biomimetic vesicles displaying H9 subtype avian influenza virus HA1 protein | |
| CA3109889A1 (en) | Immunogenic proteins and compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |